



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients

This is the author's manuscript

Original Citation:

Availability:

This version is available http://hdl.handle.net/2318/1791004 since 2022-06-14T10:52:15Z

Published version:

DOI:10.1158/1078-0432.CCR-21-0134

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



This is the author's final version of the contribution published as:

Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P, Capra A, Romano A, Liberati AM, Mannina D, de Fabritiis P, Cascavilla N, Ruggeri M, Mina R, Patriarca F, Benevolo G, Belotti A, Gaidano G, Nagler A, Hájek R, Spencer A, Sonneveld P, Musto P, Boccadoro M, Gay F. Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. Clin Cancer Res. 2021 Jul 1;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29. PMID: 33926915.

© 2021 American Association for Cancer Research.

The publisher's version is available at: <u>https://aacrjournals.org/clincancerres/article-</u> <u>abstract/27/13/3695/671504/Development-and-Validation-of-a-Simplified-</u> Score?redirectedFrom=fulltext

https://doi.org/10.1158/1078-0432.ccr-21-0134

When citing, please refer to the published version.

Link to this full text: http://hdl.handle.net/2318/1791004

This full text was downloaded from iris-Aperto: https://iris.unito.it/

2 Research article

3

1

Developing and Validating a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma (S-ERMM): Analysis from a Pooled Dataset of 2190 Patients

- 8 Running title: S-ERMM: A Simplified Early Relapse in Multiple Myeloma Score
- 9 10

7

Gian Maria Zaccaria^{1,2*}; Luca Bertamini^{1*}; Maria Teresa Petrucci³; Massimo Offidani⁴; Paolo
Corradini⁵; Andrea Capra¹; Alessandra Romano⁶; Anna Marina Liberati⁷; Donato Mannina⁸;
Paolo de Fabritiis⁹; Nicola Cascavilla¹⁰; Marina Ruggeri¹; Roberto Mina¹; Francesca
Patriarca¹¹; Giulia Benevolo¹²; Angelo Belotti¹³; Gianluca Gaidano¹⁴; Arnon Nagler¹⁵; Roman
Hájek^{16,17}; Andrew Spencer¹⁸; Pieter Sonneveld¹⁹; Pellegrino Musto^{20,21}; Mario Boccadoro¹;

- **16** Francesca Gay^{1**}
- 17
- 18 1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della
 19 Salute e della Scienza di Torino, Torino, Italy
- 20 2. Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy
- 21 3. Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto
- **22** I, Sapienza University of Rome, Rome, Italy
- **23** 4. Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy
- 5. Divisione di Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano; Università degli Studi
 di Milano, Milano, Italy
- 26 6. Department of General Surgery and Medical-Surgical Specialties, Haematology Section, University of
 27 Catania, Catania, Italy.
- 28 7. Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria, Terni, Italy
- 29 8. Division of Hematology, Azienda Ospedaliera Papardo, Messina, Italy
- 30 9. Hematology, St. Eugenio Hospital ASL Roma 2, Tor Vergata University, Rome, Italy
- 31 10. Ematologia, Ospedale "Casa Sollievo della Sofferenza" IRCCS, San Giovanni Rotondo, Italy
- 32 11. Clinica Ematologica e Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC),
- 33 Dipartimento di Area Medica (DAME), Università di Udine, Udine, Italy
- 34 12. SC Hematology, AO Città della Salute e della Scienza, Turin, Italy
- **35** 13. Hematology Division, ASST Spedali Civili Brescia, Brescia, Italy
- 36 14. Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, 28100
 37 Novara, Italy
- **38** 15. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel
- **39** 16. Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
- 40 17. Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 41 18. Alfred Health-Monash University, Melbourne, Australia
- 42 19. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- 43 20. Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine, Bari,
 44 Italy
- 45 21. Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy46
- 47 *These authors equally contributed to this manuscript and share first authorship.48

**Correspondence to: Dr. Francesca Gay, Myeloma Unit, Division of Hematology, University of Torino,
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3 - 10126 Torino,
Italy; tel: +39 0116334279; fax: +39 0116334187 (E-mail: fgay@cittadellasalute.to.it).
ORCID ID: 0000-0002-8619-412X

Keywords: multiple myeloma; early relapse; score; prognostic features; clinical trials

54 55 56

- 57 Original article
- 58 Text word count: 3873 words
- **59 Abstract word count:** 250 words
- **60** Number of references: 33
- 61 Number of tables and figures: 2 tables and 3 figures
- **62 Supplementary data:** 1 Supplementary Appendix and 6 supplementary figures (S1-S6)
- 63 Supplementary documents: TRIPOD Checklist Prediction Model Development
- 64 65

66 Authorship contributions

- 67 Conceptualization: GMZ, LB, MB, FG
- 68 Resources: all authors
- **69** Data curation: all authors
- 70 Software: GMZ, AC
- 71 Formal analysis: GMZ, LB, AC, FG
- 72 Supervision: MB, FG
- 73 Funding acquisition: none
- 74 Validation: all authors
- 75 Investigation: all authors
- 76 Visualization: GMZ, LB, AC
- 77 Methodology: GMZ, LB, FG
- 78 Writing-original draft: GMZ, LB, AC, RM, FG
- 79 Project administration: none
- 80 Writing-review and editing: all authors
- 81 All the authors approved the final version of the manuscript and agreed to be accountable for all aspects of
- 82 the work in ensuring that questions related to the accuracy or integrity of any part of the work are
- 83 appropriately investigated and resolved.
- 84 85

86 Competing interests

- 87 MTP has received honoraria from and has served on the advisory boards for Celgene, Janssen-Cilag, Amgen,
 88 Bristol-Myers Squibb, Takeda, Sanofi, and GSK.
- MO has received honoraria from and has served on the advisory boards for Amgen, Bristol-Myers Squibb,
 Celgene, GSK, Janssen, Sanofi, and Takeda.
- 91 PC has participated as lecturer and/or has served on the advisory boards for AbbVie, ADC Therapeutics,
- Amgen, Celgene, Daiichi Sankyo, Gilead, Incyte, Janssen, Jazz Pharmaceuticals, Kite, Kyowa Kirin, Novartis,
 Roche, Sanofi, Servier, and Takeda.
- 94 AML has received personal fees from Incyte; has received research funding from Novartis, Janssen, AbbVie,
- 95 Roche, Celgene, Amgen, Bristol-Myers Squibb, Takeda, Incyte, Pfizer, Beigene, Oncopeptides, Verastem,
- 96 Karyopharm, Archigen, Biopharma, Debiopharm, Morphosys, Fibrogen, and Onconova.
- 97 RM has received honoraria from Sanofi, Celgene, Takeda, and Janssen; has served on the advisory boards for
 98 Sanofi, Takeda, and Janssen; has received consultancy fees from Janssen.
- 99 FP has served on the advisory boards for Celgene and Janssen.
- **100** GB has received honoraria from Novartis, Celgene, Amgen, and Takeda.
- 101 AB has served on the advisory boards for Janssen, Celgene, and Amgen.
- 102 GG has served on the advisory boards for AbbVie, Janssen, and AstraZeneca; has served on speaker's bureaus103 for AbbVie and Janssen.
- 104 RH has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, Bristol-Myers Squibb,
- 105 Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, Bristol-Myers
- 106 Squibb, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, Bristol-Myers
- 107 Squibb, Novartis, and Takeda.
- AS has received honoraria from Celgene, Janssen, Amgen, Takeda, Secura Bio, Specialised Therapeutics
 Australia, AbbVie, Servier, Haemalogix, Sanofi, Roche, Pfizer, and Amgen; has received consultancy fees from
- Australia, AbbVie, Servier, Haemalogix, Sanofi, Roche, Pfizer, and Amgen; has received consultancy fees from
 Celgene, Janssen, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, Haemalogix, Sanofi, Roche,
- 111 Pfizer, and Amgen; has served on the speakers' bureaus for Celgene, Janssen, Takeda, and Amgen; has
- 112 received grant/research support from Celgene, Janssen, Amgen, Takeda, Servier, and Haemalogix.
- PS has served on the advisory boards for Amgen, Celgene, Genenta, Janssen, Seattle Genetics, Takeda, andKaryopharm.
- 115 PM has received honoraria from and/or served on the scientific advisory boards for Celgene, Janssen, Takeda,
- 116 Bristol-Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and GlaxoSmithKline.

- 117 MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie;
- has served on the advisory boards for Janssen and GSK; has received research funding from Sanofi, Celgene,
 Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma.
- **120** FG has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, AbbVie, and GSK; has
- 121 served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, AbbVie, GSK,
- **122** Roche, Adaptive Biotechnologies, Oncopeptides, Bluebird, and Secura Bio.
- 123 The remaining authors declare no competing financial interests.124

125 Data Sharing

- 126 After the publication of this article, data collected for this analysis and related documents will be made 127 available to others upon reasonably justified request, which has to be written and addressed to the attention
- 128 of the corresponding author Dr. Francesca Gay at the following e-mail address: fgay[*at*]cittadellasalute.to.it.
- 129 The corresponding author Dr. Francesca Gay is responsible to evaluate and eventually accept or refuse every
- 130 request to disclose data and their related documents, in compliance with the ethical approval conditions, in
- 131 compliance with applicable laws and regulations, and in conformance with the agreements in place with the 132 involved subjects, the participating institutions, and all the other parties directly or indirectly involved in the
- participation, conduct, development, management and evaluation of this analysis.

135 Financial Support

137

136 No funding was provided for this contribution.

138 Acknowledgements

- 139 GMZ acknowledges the support of European Myeloma Network (EMN) Research Italy. The authors wish to
- 140 thank all the study participants and referring clinicians for their valuable contributions.

141 Statement of translational relevance

142

Despite the huge amount of literature, there is a lack of consensus on how to better predict 143 early relapse (ER) in patients with multiple myeloma (MM). We pooled data from 7 144 European clinical trials enrolling 2190 patients with newly diagnosed MM from October 145 2003 to March 2017 to develop the Simplified Early Relapse in Multiple Myeloma (S-146 147 ERMM) score. This analysis provided further evidence of the critical role of predicting ER in MM patients, which is strongly associated with poor outcome. The S-ERMM predicted ER 148 149 by using simple and widely available baseline features. After external validation, the future development of this prognostic index may consider its combination with other static-risk 150 151 features (genomic abnormalities, circulating tumor cells) and dynamic risk evaluation (response to the therapy such as minimal residual disease) for ER prediction. The 152 153 identification of high-risk patients with dismal prognosis is the first step towards a better design of therapeutic approaches for this patient subgroup. 154 155

156

157 Abstract

158

Background. Despite the improvement of therapeutic regimens, several multiple myeloma
 (MM) patients still experience early relapse (ER). This subset of patients currently
 represents an unmet medical need.

Methods. We pooled data from 7 European multicenter phase II/III clinical trials enrolling 2190 newly diagnosed (ND)MM patients from 2003 to 2017. Baseline patient evaluation included 14 clinically relevant features. Patients with complete data (n=1218) were split into training (n=844) and validation sets (n=374). In the training set, a univariate (UV) analysis and a multivariate (MV) logistic regression model on ER within 18 months (ER18) were made. The most accurate model was selected on the validation set. We also developed

168 a dynamic version of the score by including response to treatment.

Results. The Simplified Early Relapse in MM (S-ERMM) score was modeled on 6 features weighted by a score: 5 points for high lactate dehydrogenase or t(4;14); 3 for del17p, abnormal albumin or bone marrow plasma cells >60%; and 2 for λ free-light chain. The S-ERMM identified 3 patient groups with different risks of ER18: Intermediate (Int) vs. Low (OR=2.39, p<0.001) and High vs. Low (OR=5.59, p<0.001). S-ERMM High/Int patients had significantly shorter OS (High vs. Low: HR=3.24, p<0.001; Int vs. Low: HR=1.86, p<0.001) and PFS2 (High vs. Low: HR=2.89, p<0.001; Int vs. Low: HR=1.76, p<0.001) than S-ERMM

176 Low. The Dynamic (D)S-ERMM modulated the prognostic power of the S-ERMM.

- 177 Conclusion. Based on simple, widely available baseline features, the S-ERMM and DS 178 ERMM properly identified patients with different risks of ER and survival outcomes.
- 179

181 **1. Introduction**

In the past few years, the prognosis of patients with multiple myeloma (MM) has been 182 markedly improved by the introduction of new drugs and better therapeutic strategies 183 both at diagnosis and at relapse (1-4). Traditionally, the maximal benefit in terms of 184 185 duration of remission has been observed with first-line therapies. With the use of highdose chemotherapy and autologous stem-cell transplantation (ASCT) combined with novel 186 agents or the adoption of multi-targeted agents including immunomodulatory (IMiD) 187 agents, proteasome inhibitors (PIs) and monoclonal antibodies, the current median 188 189 progression-free survival (PFS) of newly-diagnosed (ND)MM patients ranged between 41 and 50 months (4,5). Despite this remarkable improvement, still a significant proportion of 190 191 patients experiences an early relapse (ER), which has been associated with a dismal prognosis. Several studies reported the association of baseline clinical features with ER (6-192 193 12), but there is no clear consensus on what are the most important determinants; as a matter of fact, even patients without well-known high-risk features at baseline may relapse 194 195 early (7,13). Data published so far mainly come from registries or from retrospective analyses that do not systematically consider updated standard-of-care risk assessments 196

- 197 (e.g. cytogenetics, Revised-International Staging System [R-ISS]) (12).
- Unfortunately, a consensus on the appropriate definition of ER is also lacking. So far, it has
 been defined as relapse within either 12/18 months from the start of induction treatment
 (10,12) or 12/24 months from transplantation (6–9,11,14,15).
- Indeed, patients with ER have an inferior prognosis, as compared to patients who relapse later and, as such, represent a high-risk group and an unmet medical need (12,14).
- The correct identification of patient risk at baseline is the first step toward a risk-adaptive therapeutic approach. The aim of our analysis was to develop and validate the Simplified Early Relapse in Multiple Myeloma (S-ERMM), a score to predict the risk of ER based on widely available clinical and biological features. Thereafter, the S-ERMM score was re-
- 207 modulated during the patient clinical course by integrating response to therapy. We also
 208 aimed to correlate the S-ERMM with the long-term outcomes overall survival (OS) and
 209 PFS2.
- 210

211 2 Methods

212

213 **2.1** Source of data and participants

Individual patient data from 2190 NDMM patients enrolled in seven multicenter European, 214 215 open-label, phase II/III clinical trials evaluating novel agent-based therapies from October 216 2003 to March 2017 were pooled together and analyzed: NCT01093196, NCT01346787, NCT01857115, NCT01190787, NCT00551928, NCT01091831, NCT02203643 (2,3,16-20). 217 Each study was approved by ethics committees or institutional review boards at the 218 219 respective study sites and was conducted in accordance with the Declaration of Helsinki; all patients provided written informed consent. All patients received new drugs (IMiD agents 220 and/or PIs) as upfront treatment, with or without transplantation. Trial details, treatment 221 222 schedules and eligibility criteria are reported in Supplementary Tables S1A-B.

223

224 2.2 Prognostic factors and outcomes

225 Data were retrieved from electronic case-report forms (eCRFs). All the available individual 226 baseline features were analyzed. Age, creatinine levels, albumin, β 2-microglobulin (β 2m) 227 and monoclonal plasma cells in the bone marrow (BMPCs) were evaluated as continuous 228 features. According to the International Myeloma Working Group recommendations, the

- percentage of BMPCs considered was the highest in case of discrepancy between BM biopsyand BM aspirate (21).
- Free light chain (FLC, λ vs. κ), M-component subtype (IgA vs. others), lactate 231 dehydrogenase (LDH) levels >/≤upper limit of normal (ULN), presence vs. absence of 232 plasmacytomas, presence vs. absence of chromosomal abnormalities (CAs) detected by 233 interphase fluorescence *in situ* hybridization [iFISH; del17p, t(4;14), t(14;16), t(11;14)] 234 were evaluated as categorical values. iFISH analysis was centralized in one laboratory (see 235 the Supplementary Methods). High-risk CAs were defined as the presence of del(17p) 236 and/or t(4;14) and/or t(14;16). (22) The cut-offs for del(17p) and IgH translocation were 237 10% and 15%, respectively. Baseline R-ISS stage (II/III vs. I) was also included in the 238 prognostic factor evaluation (23). Patients with complete data were then split into training 239 and validation sets. In the validation set, patients treated with more innovative and 240 effective therapies were included. These patients also had a shorter median follow-up. 241
- Based on the available literature, two cut-offs for ER were evaluated: 18 (ER18) and 24 242 (ER24) months from diagnosis. In the ER18 analysis, patients who died for reasons other 243 244 than progressive disease (PD) or who withdrew consent within 18 months were excluded from the analysis because they were not at risk of progression for the entire first 18 245 months. Patients experiencing PD within 18 months from diagnosis were included in the 246 ER18 population; those not experiencing PD within 18 months were included in the 247 248 reference population. The reference population was then divided into 2 groups: patients experiencing PD after 18 months from diagnosis at the time of their last follow-up (Late 249 250 relapse group) and patients who were free from progression at the time of their last follow-251 up (No PD group).
- Methods for the ER24 analysis were similar, but they included a cut-off of 24 months after diagnosis (see the Supplementary Appendix). The results regarding the best cut-off are reported in the main text of this contribution. For the sake of completeness, the other analyses are included in the Supplementary Appendix.
- OS was calculated from the start of treatment until the date of death or the date the patient
 was last known to be alive. PFS2 was calculated from the start of treatment until the date of
 PD after the second line of treatment (second PD) or death (regardless of the cause of
 death), whichever came first. Other clinical endpoints are detailed in the Supplementary
 Methods.
- 261

262 2.3 Statistical analysis

From the training set, a univariate analysis (UV) on ER18 as outcome was performed 263 264 according to chi-square and Kruskal-Wallis tests, as appropriate. Features with p<0.1 were then tested in a multivariate (MV) logistic regression model. We compared 2 MV analyses, 265 one including the R-ISS and the other including individual features defining the R-ISS (LDH, 266 albumin, β2m and CAs). In order to account for potential confounders, each MV analysis 267 268 was adjusted for age. Subsequently, each MV analysis was identified through a backward selection based on the minimization of the Akaike Information Criterion to identify 269 independent prognostic factors. Continuous parameters were not categorized a priori 270 because this would have negatively affected the power of the analysis. After selecting the 271 272 best MV model, the optimal cut-offs for the most significant continuous features were re-273 evaluated by spline function. MV models were used to estimate odds ratio (OR) for ER18 risk, 95% confidence intervals (CIs) and p-values. 274

Each model was tested on the validation set by assessing the area under the curve (AUC), in
order to select the most accurate model including individual features or features
aggregated into the R-ISS.

278 Once the most accurate model was selected, three prognostic groups of patients with Low, 279 Intermediate (Int) and High risk of ER were defined by categorizing the linear predictors of the final MV logistic model. Hence, two optimal cut-points were found maximizing the ORs 280 defined by the MV in the training set. A scalar score was thus proportionally assigned to 281 each predictor according to the coefficients of the final MV model. As the linear score, two 282 optimal cut-points were found maximizing the ORs defined by the MV in both the training 283 and validation sets. Thus, we developed the S-ERMM score, which identified three different 284 groups of patients with Low, Int, and High risks of ER18. Other statistical survival analyses 285 are detailed in the Supplementary Methods. 286

In order to integrate baseline prognostic evaluation and response to treatment, we 287 developed the Dynamic (D)S-ERMM, a logistic model that included S-ERMM score and 288 achievement of at least a very good partial response (\geq VGPR). Since this score included 289 response, it should not be assessed at baseline, but at a subsequent timepoint after 290 treatment, in order to re-modulate patient risk during therapy (dynamic risk score). We 291 therefore analyzed data from a landmark point, which was set at the median time to 292 293 achieve \geq VGPR and included only patients who did not relapse before the landmark point. We assessed the role of ≥VGPR and S-ERMM in a MV logistic regression model to predict 294 295 ER18. The DS-ERMM was modeled on the proportional coefficients obtained from the MV model. To measure the prognostic performances on this sub-cohort, we compared the 296 297 concordance (C)-index assessed in both models (24).

Statistical analysis was performed using R (v.3.5.2). We used the Transparent Reporting of
a Multivariable Prediction Model for Individual Prognosis Or Diagnosis (TRIPOD) criteria
to validate our methods (25,26).

301

302 **3 Results**

303

304 3.1 Patient characteristics

305 Data from 2190 patients were available; 3 patients were excluded because of screening306 failure.

In the ER18 analysis, 50 patients died for reasons other than PD and 51 withdrew their
consent within 18 months and were excluded; patients eligible for the analyses were 2086.
Patients with complete data (n=1218) were then split into training (n=844) and validation
(n=374) sets and included in the logistic regression analysis.

311 Training set: in the overall population (median follow-up 70 months, interquartile range [IQR]=48-81 months), the median age was 66 years, 73% of patients presented with R-ISS 312 stage II/III, 10% with LDH>ULN; 14% with del(17p), 14% with t(4;14). Patients with 313 BMPCs>60% were 29% and 36% had λ FLC. A total of 312/844 (37%) patients 314 315 experienced ER18. Patients in the ER18 vs. the reference population were significantly older (p=0.026), had higher β 2m (p<0.001) and lower albumin (p<0.001) levels; a higher 316 proportion of patients had LDH>ULN (p=0.001), t(4;14) (p<0.001), R-ISS stage II/III 317 318 (p<0.001), del17p (p=0.005) and BMPCs>60% (p=0.001; Table 1).

Validation set: in the overall population (median follow-up 35 months, IQR 29-41), the median age was 57 years, which was significantly lower (p<0.001) than that in the training set. Patients who experienced ER18 were 61/374 (16%). The distribution of baseline features between ER18 and the reference population was similar to that in the training set, except for the absence of significant difference in the proportion of patients with BMPCs>60% and del(17p), although this may be related to the smaller sample size (Table 1). The median time to \geq VGPR was 9 months in the training set and 3 months in the validation set. \geq VGPR at 9 months was achieved in 40% and 81% of patients in the training and validation sets, respectively.

329 330

331 3.2 Best model of ER

Based on the UV analysis of patients who experienced ER18, 10/14 features were included in the MV analysis: age, FLC, BMPCs, del17p, t(4;14), t(14;16), albumin, β 2m, LDH, and R-ISS stage. In the MV analysis incorporating the R-ISS, age, R-ISS II/III vs. I and increased BMPCs increased the risk of ER18. When the MV analysis was performed including single features defining the R-ISS, increased BMPCs, λ FLC, LDH>ULN, presence of del17p, and t(4;14) increased the probability of ER18 (Table 2).

Each MV model was then tested on the validation set. The AUC was 0.62 (95% CI=0.55-0.69) for the ER18 model including the R-ISS and 0.66 (95% CI=0.58-0.73) for the ER18 model incorporating individual features. The ER18 model incorporating individual features resulted in the highest AUC (0.66) and was therefore selected to develop the S-ERMM score.

343 UV and MV ER24 analyses and the AUC in the validation set are reported in the344 Supplementary Results and in Table S3.

- 345
- 346

347 3.3 S-ERMM score

The ER18 linear index was calculated as $0.047 \times BMPCs \%/5 + 0.589 \times LDH/ULN$ (IF LDH>ULN) + 0.459 × del17p (IF present) + 0.705 × t(4;14) (IF present) + 0.293 × FLC (IF λ) - 0.284 × albumin.

In the training set, the linear score significantly discriminated three patient groups (High, intermediate [Int] and Low risk) with significantly different risks of ER18 (Figure 1).

BMPC and albumin levels were dichotomized according to the optimal cut-off: high BMPC level if >60% and abnormal albumin level if ≤ 3.5 or ≥ 5 (Figure S1).

The S-ERMM score (<u>https://sermm.emnitaly.org/</u>) was mathematically consistent with the linear index and was defined including 6 features identified in the MV analysis: 5 points for LDH>ULN or the presence of t(4;14); 3 points for the presence of del17p, abnormal

albumin and BMPCs>60%; and 2 points for the presence of λ FLC (Figure 1).

The Low-risk group included patients with a total score ≤ 5 (68% of patients in the training

set, 29% of whom experienced an ER18); the Int-risk group patients with a total score

between 6 and 10 (25% of patients in the training set, 50% of whom with ER18); and the

High-risk group patients with a total score ≥ 11 (7% of patients in the training set, 70% of

- whom with ER18). In the training set, the S-ERMM significantly discriminated three groups of patients with different risks of ER18: Int vs. Low (OR=2.39, 95% CI=1.73-3.30, p<0.001)
- and High vs. Low (OR=5.59, 95% CI=3.08-10.16, p<0.001). The S-ERMM was confirmed in
- the validation set: Int vs. Low (OR=2.27, 95% CI=1.23-4.17, p=0.008) and High vs. Low

367 (OR=4.87, 95% CI=2.01-11.76, p=0.001). The impact of the S-ERMM on the ER18 risk was 368 higher than that of each single feature.

- 369 In the DS-ERMM analyses, the training population (n=673) included patients evaluable for
- response at 9 months (median time to \geq VGPR), 162 (24%) of whom experienced ER18. In
- 371 this population, both the S-ERMM and the achievement of \geq VGPR were statistically
- independent predictors of ER in the MV analysis (Figure S2).
- The DS-ERMM score was defined as the S-ERMM score obtained at baseline minus 4 points
- in case of achievement of \geq VGPR. Patients who reached the 9-month cut-off (which was not

375 reached by 171 patients, 150 of whom relapsed/died before), were thus reclassified in 376 three groups: the Low-risk group included 250 patients (37%) with a total score ≤ 0 (only 12% of whom experienced an ER18); the Int-risk group included 271 patients (40%) with a 377 378 total score between 1 and 5 (only 24% of whom with ER18); and the High-risk group included 152 patients (23%) with a total score ≥ 6 (45% of whom with ER18). These three 379 groups had different risks of ER18 (Figure S3): Int vs. Low (OR=2.36, 95% CI=1.46-3.80, 380 p<0.001) and High vs. Low (OR=6.34, 95% CI=3.84-10.46, p<0.001). 381 In the validation set, there were no significant differences in terms of risk of ER18 between 382

- In the validation set, there were no significant differences in terms of risk of ER18 between
 DS-ERMM Int vs. Low, while a trend towards a higher risk was observed in the High vs. Low
 comparison (OR=2.40; p=0.09; see the Supplementary Results).
- Following the application of the S-ERMM score at baseline and the re-modulation of patient risk at 9 months according to DS-ERMM (for those patients who did not relapse during the first 9 months), 20% of patients in the total population of the training set were classified as High-risk patients, 39% as Int-risk patients, and 41% as Low-risk patients.
- 389

390 3.4 Survival analysis

A landmark analysis with landmark point at 18 months was performed. OS and PFS2 were significantly shorter in the ER18 population than in the reference population and the Late relapse and No relapse populations (Figures S4A-D). Similarly, ER18 patients showed an inferior outcome after relapse (Supplementary Results and Figure S5).

- The median OS was 31.5 months in patients with S-ERMM High, 59.5 with S-ERMM Int and not reached (NR) with S-ERMM Low. Median PFS2 was 19.8 months in patients with S-ERMM High, 40.0 months with S-ERMM Int and 62.3 months with S-ERMM Low. OS and PFS2 were significantly shorter in S-ERMM Int vs. S-ERMM Low patients (OS, HR=1.86, 95% CI=1.48-2.33; PFS2, HR=1.76, 95% CI=1.45-2.14; both p<0.001) and in S-ERMM High vs. S-ERMM Int patients (OS, HR=1.74, 95% CI=1.22-2.50, p=0.002; PFS2, HR=1.64, 95% CI=1.18-2.28; p=0.003; Figure 2). The median PFS was 31.6 months in S-ERMM Low, 17.3
- 402 months in S-ERMM Int, and 13.2 months in S-ERMM High patients.
- 403 Subgroup analyses for OS according to first-line treatment confirmed the prognostic role of S-ERMM in ASCT-ineligible patients (Int vs. Low, HR=1.75, 95% CI=1.30-2.35, p<0.001; 404 High vs. Int, HR=1.85, 95% CI=1.10-3.11, p=0.020) and in ASCT-eligible patients (Int vs. 405 406 Low, HR=1.94, 95% CI=1.36-2.78, p<0.001; High vs. Int, HR=1.81, 95% CI=1.09-3.01, p=0.022) (Figure S6); in PI-treated patients (Int vs. Low, HR=1.73, 95% CI=0.93-3.20, 407 p=0.083; High vs. Int, HR=3.13, 95% CI=1.21-8.08, p=0.018); and in patients treated with 408 IMiD agents (Int vs. Low, HR=1.85, 95% CI=1.45-2.37; p<0.001; High vs. Int, HR=1.64, 95% 409 410 CI=1.11-2.43, p=0.013).
- 411 According to DS-ERMM, OS and PFS2 were significantly shorter in DS-ERMM Int vs. DS-412 ERMM Low patients (OS, HR=1.96, 95% CI=1.44-2.66; PFS2, HR=1.86, 95% CI=1.44-2.38; 413 both p<0.001) and in DS-ERMM High vs. DS-ERMM Low patients (OS, HR=3.28, 95% 414 CI=2.37-4.54, p<0.001; PFS2, HR=2.91, 95% CI=2.22-3.82; p<0.001; Figure 3).
- 415

416 **4 Discussion**

417 Several studies reported dismal survival outcomes in MM patients experiencing an ER; 418 however, the definition of ER varies from study to study, and consensus is still lacking. Also, 419 the impact of well-known disease-related risk factors (e.g., albumin, β 2m, CAs by iFISH and 420 LDH) on the risk of ER has not been thoroughly assessed in NDMM patients. The correct 421 evaluation of baseline ER risk thus remains an unmet medical need. We confirmed ER with an 18-month cut-off as a strong predictor of the long-term outcomes' OS and PFS2 in the context of novel-treatment approaches (e.g., PIs, IMiD agents and ASCT). Our decision of adopting the 18-month cut-off for the definition of ER was also supported by the available literature, in which most of the studies defined ER as both 18 months from diagnosis and 12 months from ASCT (6–10,12,27).

We developed the S-ERMM score by identifying and integrating 6 features that predicted the risk of ER (presence of t(4;14), del17p, LDH>ULN, BMPCs>60%, abnormal albumin and λ FLC). S-ERMM is a simple tool enabling the identification of 3 patient groups with significantly different risks of ER (Figure 2) and significantly different PFS2 and OS. In particular, S-ERMM High patients had a median OS of 31 months, significantly shorter than that of S-ERMM Int (median 60 months) and S-ERMM Low patients (median NR after 6 years of follow-up).

Although several studies tried to correlate ER risk with clinical and biological features (6–
9,11,12,14), most of them did not cover all of the recognized MM prognostic factors (23)
[e.g. extensive CA analysis (8,9,14) and LDH assessment (10)]. In our series, we included
widely available and well-recognized baseline features. The S-ERMM score included
albumin levels (which reflect the inflammatory state at diagnosis) (28), high-risk CAs
(del17p and t(4;14), associated with a biologically aggressive disease), and high LDH (29)
and BMPC levels (associated with tumor burden) (30).

441 The majority of analyses published so far on ER in MM are single-center or retrospective studies. To the best of our knowledge, only Bygrave et al. analyzed young ASCT-eligible 442 patients enrolled in a single clinical trial (7). Indeed, in our analysis, data from clinical trials 443 444 underwent a systematic data assessment, with baseline features assessment, centralized 445 laboratory analyses and uniform evaluation of response and clinical outcomes (31). In this light, the development and validation of the S-ERMM score in a population consisting of 446 447 both young (transplant-eligible) and elderly (>65 years) patients enrolled in 4 phase II/III clinical trials treated with novel agents from different drug classes with or without ASCT 448 449 support the application of this score to NDMM patients. On the other hand, this is a selected population of European clinical trials that indeed needs validation in real-life settings. 450

Response to therapy is a strong predictor of better OS and PFS2 (15), and the achievement 451 of a deep response (minimal residual disease [MRD] negativity) may abrogate the poor 452 prognosis conferred by high-risk FISH at diagnosis. Therefore, the importance of 453 454 integrating static (baseline) and dynamic (response) prognostic features led to the incorporation of response to treatment (\geq VGPR) into the S-ERMM score. The assessment of 455 456 the S-ERMM score at the time of diagnosis and the re-modulation of patient risk at 9 months (for those patients who did not relapse during the first 9 months) improved our 457 ability to detect ER patients. In fact, in the initial population of our analysis, only 7% of 458 patients were included in the high-risk group (S-ERMM High), while 68% of patients were 459 included in the S-ERMM Low group (29% of whom had an ER18) and 25% in the S-ERMM 460 Int group (50% of whom had an ER18). Of note, in the DS-ERMM analysis, the Low-risk 461 group included only 37% of patients (with only 12% who had an ER18) and the Int-risk 462 group 40% of patients (with only 24% who had an ER18). Ultimately, using sequentially 463 these two scores in the overall population, 20% of patients were determined to be at High 464 465 risk, 39% at Int risk, and 41% at Low risk. This improvement in the evaluation of patient risk of ER highlighted the role of the dynamic modulation of patient risk at baseline. 466

467 Unfortunately, in the validation set, there were no significant differences in terms of risk of
468 ER18 between DS-ERMM Int vs. Low, while trends towards a higher risk were observed in
469 the High vs. Low comparison.

470 Of note, the optimal response (degree and timing) to be incorporated as a dynamic factor

471 should consider the type of patient population and the availability of treatment options:

472 these two factors determine the choice of a specific therapy, with different degrees of 473 efficacy and time to best response. In the validation set, the rate of \geq VGPR was definitely higher than in the training set and the median time to response was lower. We presume 474 475 that the assessment of a deeper response, such as the achievement of MRD negativity, could better discriminate patients in the context of novel, highly effective therapies. 476 Unfortunately, MRD evaluation was not available in most of the trials included in the 477 training set and could not be used as optimal response to recalculate the risk of ER after 478 479 therapy. Still, our main aim was to identify patients at risk of ER using risk assessment at 480 diagnosis, and the S-ERMM score was prognostic in the context of both older (training set) 481 and more recent (validation set) drug regimens.

- Our analysis has some limitations. First, the risk classification based on the S-ERMM score
 was designed to better identify patients at high risk of ER and, as a consequence, was
 unbalanced, with only a small proportion of patients in the S-ERMM High group.
 Nevertheless, the risk group stratification improved after the re-modulation of risk
 assessment by using the DS-ERMM score.
- 487 Another limitation was the low number of patients treated upfront with a combination of PIs and IMiD agents in the training set, since this currently represents a standard of care 488 for both young and elderly patients. Nevertheless, our results were validated in a 489 population who received intensive and effective induction and consolidation therapies 490 491 including the second-generation PI carfilzomib with or without IMiD agents and ASCT intensification. In this context, the S-ERMM maintained its prognostic role, but the 492 percentage of patients experiencing ER was definitely lower than that reported in the 493 494 training set.
- 495 In conclusion, we were able to correctly classify a good proportion of patients who experienced early relapse by assessing the S-ERMM score at baseline and re-modulating 496 patient risk at 9 months with the DS-ERMM score. An external validation of the S-ERMM 497 and DS-ERMM scores is warranted, especially in patients treated with combinations of PIs, 498 499 IMiD agents, and anti-CD38 monoclonal antibodies. Our ability to predict ER could also be improved by the inclusion of other risk features at baseline with known prognostic impact, 500 501 such as amp(1q21), TP53 mutational status, and circulating plasma cells (27,32,33). 502 Unfortunately, these data were not available for this analysis.
- The correct identification of patient risk at diagnosis and during therapy is an essential
 step towards a risk-adapted approach, the cure of patients, and the prevention of over- and
 under-treatment.

506

507 **5 References**

- 508
- 5091.Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved510survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–51120.
- Palumbo A, Cavallo F, Gay F, Di Raimondo F, Yehuda DB, Petrucci MT, et al. Autologous
 transplantation and maintenance therapy in multiple myeloma. N Engl J Med.
 2014;371:895–905.
- Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy
 plus lenalidomide versus autologous transplantation, followed by lenalidomide plus
 prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A
 randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617–29.
- Attal M, Lauwers-cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide,
 bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med.
 2017;376:1311–20.
- 5. Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term 523 follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and 524 dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously 525 untreated multiple myeloma without an intent for immediate autologous stem . Blood 526 Cancer J. Springer US; 2020;10.
- 527 6. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of 528 early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant. 529 2008;42:413–20.
- 530 7. Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, et al. Early relapse after
 531 high-dose melphalan autologous stem cell transplant predicts inferior survival and is
 532 associated with high disease burden and genetically high-risk disease in multiple
 533 myeloma. Br J Haematol. 2020;Epub ahead of print.
- 5348.Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse535after single auto-SCT for multiple myeloma is a major predictor of survival in the era of536novel agents. Bone Marrow Transplant. 2015;50:204–8.
- 9. Ong SY, De Mel S, Chen YX, Ooi MG, Surendran S, Lin A, et al. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: Analysis of the Singapore Multiple Myeloma Working Group. Bone Marrow Transplant. 2016;51:933–7.
- 54110.Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, et al. Early relapse after542autologous transplant for myeloma is associated with poor survival regardless of543cytogenetic risk. Haematologica. 2019;105:E480–3.
- Helm-Petersen S, Sørrig R, Klausen TW, Preiss B, Frølund UC, Helleberg C, et al. Early
 relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on
 the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia.
 2018;32:2054–7.
- 548 12. Majithia N, Rajkumar S V, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse
 549 following initial therapy for multiple myeloma predicts poor outcomes in the era of novel
 550 agents. Leukemia. 2016;30:2208–13.
- Durie BGM, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma
 frontline therapy does not predict outcome: Importance of time to progression in
 Southwest Oncology Group chemotherapy trials. J Clin Oncol. 2004;22:1857–63.
- 554 14. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, et al. Early relapse after

- 555autologous hematopoietic cell transplantation remains a poor prognostic factor in556multiple myeloma but outcomes have improved over time. Leukemia. 2018;32:986–95.
- 557 15. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, et al. Revised
 558 International Staging System Is Predictive and Prognostic for Early Relapse (<24 months)
 after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood
 560 Marrow Transplant. Elsevier Inc.; 2019;25:683–8.
- Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, et al. Triplet vs
 doublet lenalidomide-containing regimens for the treatment of elderly patients with
 newly diagnosed multiple myeloma. Blood. 2016;127:1102–8.
- Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, et al. Carfilzomib,
 cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple
 myeloma: A multicenter, phase 2 study. Blood. 2014;124:63–9.
- Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, et al. A phase 2 study
 of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients
 with untreated multiple myeloma. Leukemia. 2016;30:1320–6.
- Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib-Melphalan Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide
 Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple
 Myeloma: A Randomized Controlled Trial. J Clin Oncol. 2010;28:5101–9.
- S74 20. Gay F, Bertamini L, Zaccaria GM, Aquino S, Spadano A, Siniscalchi A, et al. PREDICTORS
 S75 OF EARLY RELAPSE IN YOUNG MULTIPLE MYELOMA PATIENTS: INTEGRATED ANALYSIS OF
 S76 BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY.
 S77 HemaSphere. 2020;4:457 [Abstract #EP999, EHA 2020 25th Congress].
- 578 21. Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, et al.
 579 European Myeloma Network recommendations on tools for the diagnosis and
 580 monitoring of multiple myeloma: what to use and when. Haematologica.
 581 2018;103:1772–84.
- Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment
 of multiple myeloma with high-risk cytogenetics: A consensus of the International
 Myeloma Working Group. Blood. 2016;127:2955–62.
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised
 international staging system for multiple myeloma: A report from international myeloma
 working group. J Clin Oncol. 2015;33:2863–9.
- 58824.Therneau TM, Watson DA. The concordance statistic and the Cox model. Technical589Report #85. Rochester (US-MN): Department of Health Sciences, Mayo Clinic; 2017.
- 590 25. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable
 591 prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement.
 592 Ann Intern Med. American College of Physicians; 2015;162:55–63.
- Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al.
 Transparent reporting of a multivariable prediction model for individual prognosis or
 diagnosis (TRIPOD): Explanation and elaboration. Ann Intern Med. American College of
 Physicians; 2015;162:W1–73.
- 59727.D'Agostino M, Zaccaria GM, Ziccheddu B, Rustad EH, Genuardi E, Capra A, et al. Early598Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-599generation Sequencing. Clin Cancer Res. Clin Cancer Res; 2020;26:4832–41.
- 60028.Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International601staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.
- 602 29. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase

- level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern
 Med. 1991;115:931–5.
- Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al.
 International Myeloma Working Group updated criteria for the diagnosis of multiple
 myeloma. Lancet Oncol. 2014;15:e538-48.
- 31. Zaccaria GM, Ferrero S, Rosati S, Ghislieri M, Genuardi E, Evangelista A, et al. Applying
 data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL)
 ensures superior data quality and improved assessment of clinical outcomes. JCO Clin
 Cancer Informatics. 2019;1–15.
- Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of
 Chromosome 1q is associated with early progression in multiple myeloma patients
 treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. Springer
 US; 2019;9:Article number 94.
- Bertamini L, Grasso M, D'Agostino M, Pascarella A, Tosi P, Monaco F, et al. Poor
 Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is
 Independent from Other High-Risk Features but Is Modulated By the Achievement of
 Minimal Residual Disease Negativity. Blood. American Society of Hematology;
 2020;136:12-13 [Abstract #720, ASH 2020 62nd Meeting].
- 621
- 622

6 Tables

	POOLED-SET	TRAINING SET*				VALIDATION SET*				
	Overall population	Overall population	ER18 population	Reference population	р	Overall population	ER18 population	Reference population	р	
N of patients (%)	2190	844	312 (37)	532 (63)	-	374	61 (16)	313 (84)	-	
Age, y Median [IQR]	63.0 [56.0, 72.0]	66.0, [57.0- 73.0]	68.0 [58.0, 75.0]	65.0 [57.0, 73.0]	0.026	57.0 [51.0, 62.0]	56.0 [48.0, 62.0]	58.0 [52.0, 62.0]	0.173	
Missing N (%)	0 (0)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
Albumin, g/dL: Median [IQR]	3.8 [3.4, 4.2]	3.8, [3.4-4.2]	3.7 [3.2, 4.1]	3.9 [3.5, 4.2]	<0.001	3.9 [3.5, 4.3]	3.7 [3.4, 4.1]	3.9 [3.5, 4.3]	0.046	
Missing N (%)	10 (0.5)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
β2m, mg/dL: Median [IQR]	3.4 [2.4, 5.1]	3.6, [2.5-5.4]	4.1 [2.8, 6.1]	3.3 [2.4, 5.0]	<0.001	2.9 [2.0, 4.2]	3.7 [2.2, 5.8]	2.8 [2, 4]	0.015	
Missing N (%)	8 (0.4)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
LDH>ULN, N (%)	211 (9.6)	83 (10)	45 (14)	38 (7)	0.001	54 (14)	17 (28)	37 (12)	0.002	
Missing N (%)	267 (12.2)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
del17p: N (%)	246 (11.2)	121 (14)	59 (19)	62 (12)	0.005	52 (14)	11 (18)	41 (13)	0.414	
Missing N (%)	477 (21.8)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
t(4;14): N (%)	228 (10.4)	117 (14)	63 (20)	54 (10)	<0.001	57 (15)	17 (28)	40 (13)	0.005	
Missing N (%)	482 (22.0)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
t(11;14): N (%)	341 (15.5)	156 (18)	50 (16)	106 (20)	0.188	87 (23)	14 (23)	73 (23)	1	
Missing N (%)	522 (23.8)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
t(14;16): N (%)	78 (3.6)	32 (4)	16 (5)	16 (3)	0.171	19 (5)	4 (7)	15 (5)	0.798	
Missing N (%)	506 (23.1)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		
R-ISS, II/III: N (%)	1388 (63.5)	613 (73)	255 (82)	358 (67)	<0.001	250 (67)	53 (87)	197 (63)	<0.001	
Missing N (%)	388 (17.7)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)		

Table 1. Patient characteristics of the overall population, stratified according to the ER18 outcome as training set and validation set

Creatinine, mg/dL: Median [IQR]	0.9 [0.7, 1.1]	0.9 [0.8-1.2]	1.0 [0.8, 1.2]	0.9 [0.8, 1.1]	0.136	0.8 [0.7, 1.0]	0.8 [0.7, 1.2]	0.8 [0.7, 1.0]	0.427
Missing N (%)	67 (3.1)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	
BMPCs, >60% N (%)	612 (28)	243 (29)	112 (36)	131 (25)	0.001	139 (37)	27 (44)	112 (36)	0.267
Missing N (%)	121 (5.5)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	
FLC, λ: N (%)	727 (36)	301 (36)	123 (39)	178 (33)	0.095	143 (38)	18 (30)	125 (40)	0.165
Missing N (%)	0 (0)	0 (0)	O (O)	0 (0)		0 (0)	0 (0)	0 (0)	
M component, IgA: N (%)	451 (21)	186 (22)	65 (21)	121 (23)	0.575	57 (15)	10 (16)	47 (15)	0.937
Missing N (%)	3 (0.1)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	
Plasmacytomas, N (%)	266 (12)	78 (9)	27 (9)	51 (10)	0.743	49 (13)	10 (16)	39 (12)	0.532
Missing N (%)	0 (0)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	

*Patients with complete data only.

Abbreviations. N, number; y, years; ER, early relapse within 18 months from diagnosis; IQR, interquartile range; $\beta 2m$, $\beta 2$ -microglobulin; LDH, lactate dehydrogenase; ULN, upper limit of normal; del17p, deletion 17p; t, translocation; R-ISS, Revised International Staging System; BMPCs, bone marrow plasma cells; FLC, free light chains; M, monoclonal.

	ER18*								
	Analy	sis including R-ISS	Analysis including single features						
	UV Analysis	MV Analys	is	UV Analysis	MV Analysis				
	р	OR (95% CI)	р	р	OR (95% CI)	р			
Age, (increased by 1 y)	0.026	1.01 (1.00 - 1.02)	0.113	0.026	1.01 (1.00 - 1.03)	0.094			
Albumin, (increased by 1 mg/dL)				<0.001	0.75 (0.60 - 0.95)	0.015			
β2m, (increased by 1 mg/dL)				<0.001	-	-			
LDH (> vs. ≤ULN) del17p				0.001	2.03 (1.27 - 3.26)	0.003			
(presence vs. no) t(4;14)				0.005	1.65 (1.10 - 2.47)	0.016			
(presence vs. no)				<0.001	2.12 (1.40 - 3.19)	<0.001			
R-ISS (II/III vs. I) BMPCs %	<0.001	1.91 (1.35 - 2.71)	<0.001						
(increased by 5%) FLC	<0.001	1.05 (1.02 - 1.08)	<0.001	<0.001	1.06 (1.03 - 1.09)	<0.001			
FLC (λ vs. κ)	0.095	-	-	0.095	1.31 (0.97 - 1.78)	0.076			

Table 2. Univariate (UV) and multivariate (MV) analyses of the baseline features to predict ER18

* Only significant features (p<0.1) in UV analysis and age were included.

- Excluded before the MV analysis by the Akaike information criterion (AIC).

Abbreviations. ER18, early relapse within 18 months from diagnosis, R-ISS Revised International Staging System; UV, univariate; MV, multivariate; OR, odds ratio; CI, confidence interval; β 2m, β 2-microglobulin; LDH, lactate dehydrogenase; ULN, upper limit of normal; del17p, deletion 17p; t, translocation; R-ISS, Revised International Staging System; BMPCs, bone marrow plasma cells; FLC, free light chains; M, monoclonal.

7 Figures: titles and legends

Figure 1. Flowchart of the S-ERMM score construction

Abbreviations. ER, early relapse; features, features; BMPCs, bone marrow plasma cells; LDH, lactate dehydrogenase; ULN, upper limit of normal; del17p, deletion 17p; t, translocation; FLC, free light chains; alb, albumin; Low, low; Int, intermediate; High, high; coeff., coefficient; OR, odds ratio; CI, confidence interval; p, p-value; S-ERMM, Simplified Early Relapse in Multiple Myeloma score.

Figure 2. OS (A) and PFS2 (B) stratified by S-ERMM score

A) OS: S-ERMM Int vs. S-ERMM Low, S-ERMM High vs. S-ERMM Low and S-ERMM High vs. S-ERMM Int. B) PFS2: S-ERMM Int vs. S-ERMM Low, S-ERMM High vs. S-ERMM Low and S-ERMM High vs. S-ERMM Int.

Abbreviations. OS, overall survival; PFS2, progression free survival-2; S-ERMM, Simplified Early Relapse in Multiple Myeloma score; Int, intermediate; HR, hazard ratio; CI, confidence interval; p, p-value.

Figure 3. OS (A) and PFS2 (B) according to the DS-ERMM score

Landmark analysis at 9 months, corresponding to the median time to achieve ≥VGPR. A) OS: DS-ERMM Int vs. DS-ERMM Low, DS-ERMM High vs. DS-ERMM Low, and DS-ERMM High vs. DS-ERMM Int. B) PFS2: DS-ERMM Int vs. DS-ERMM Low, DS-ERMM High vs. DS-ERMM Low and DS-ERMM High vs. DS-ERMM Int.

Abbreviations. OS, overall survival; PFS2, progression-free survival-2; DS-ERMM score, Dynamic Simplified Early Relapse in Multiple Myeloma score; VGPR, very good partial response; Int, intermediate; HR, hazard ratio; CI, confidence interval; p, p-value.

The ER score was calculated as 0.047 × BMPCs %/5 + 0.589 × LDH (IF >ULN) + 0.459 × del17p (IF present) + 0.705 × t(4;14) (IF present) + 0.293 × FLC (IF FLC= λ) - 0.284 × albumin

> Int vs. Low \rightarrow OR=2.51, 95% CI=1.81–3.48, p<0.001 High vs. Low \rightarrow OR=4.59, 95% CI=2.45-8.61, p<0.001

> Int. vs. Low \rightarrow OR=2.52, 95% CI=1.36–4.68, p=0.003 High vs. Low -> OR=5.55, 95% CI=2.58–14.22, p<0.001

Model selected for the definition of the score: ER18 involving 6/14 fts: BMPCs , LDH>ULN, del17p, t(4;14), FLC, albumin

Categorization of continuous variables BMPCs (>60%) and albumin (\geq 3.5 and \leq 5)

Definition of the S-ERMM score: BMPCs \rightarrow Beta Coeff. proportionality: 1.7 \rightarrow score: 3 albumin \rightarrow Beta Coeff. proportionality: 1.6 \rightarrow score: 3 del17p \rightarrow Beta Coeff. proportionality: 1.8 \rightarrow score: 3 $t(4;14) \rightarrow Beta Coeff. proportionality: 2.8 \rightarrow score: 5$ LDH>ULN \rightarrow Beta Coeff. proportionality: 2.7 \rightarrow score: 5 **FLC** \rightarrow **Beta Coeff. proportionality:** 1.0 \rightarrow **score:** 2


Figure 1

Training Set

Int vs. Low \rightarrow OR=2.39, 95% CI=1.73-3.30, p<0.001 High vs Low \rightarrow OR=5.59, 95% CI=3.08–10.16, p<0.001

Validation Set

Int vs Low → OR=2.27, 95% CI=1.23–4.17, p=0.008 High vs Low → OR=4.87, 95% CI=2.01–11.76, p=0.001



Number at risk (censored)





Figure 2



DS-ERMM: Int vs. Low, HR: 1.96 (95% CI: 1.44 - 2.66, p<0.001) DS-ERMM: High vs. Low, HR: 3.28 (95% CI: 2.37 - 4.54, p<0.001) DS-ERMM: High vs. Int, HR: 1.68 (95% CI: 1.27 - 2.22, p<0.001)




Figure 3